CompuGroup Medical SE & Co. KGaA (CMPUY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CompuGroup Medical SE & Co. KGaA (CMPUY) with AI Score 48/100 (Weak). CompuGroup Medical SE & Co. KGaA is a global healthcare IT company providing software and IT solutions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026CompuGroup Medical SE & Co. KGaA (CMPUY) Healthcare & Pipeline Overview
CompuGroup Medical SE & Co. KGaA, a German-based healthcare IT firm, delivers software and IT solutions across four segments: Ambulatory, Pharmacy, Hospital, and Consumer Health. With a global presence and a focus on digital healthcare solutions, the company supports healthcare providers and consumers, holding a significant position in the healthcare information services sector.
Investment Thesis
CompuGroup Medical SE & Co. KGaA presents a mixed investment thesis. The company's established presence in the healthcare IT sector and diverse product portfolio across ambulatory, pharmacy, hospital, and consumer health segments provide a stable revenue base. The company's P/E ratio is 89.71, and the profit margin is 1.5%. Growth catalysts include expanding digital health solutions and increasing demand for integrated healthcare systems. Potential risks include intense competition, evolving regulatory landscapes, and the relatively low profit margin. The company's beta of 0.82 suggests lower volatility compared to the market. The dividend yield is 0.22%.
Based on FMP financials and quantitative analysis
Key Highlights
- CompuGroup Medical operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS).
- The company serves a global market, providing healthcare IT solutions to various healthcare providers and consumers.
- CompuGroup Medical's gross margin stands at 83.6%, indicating strong pricing power and efficient cost management in its software and IT solutions.
- The company's market capitalization is $1.19 billion, reflecting its significant presence in the healthcare IT sector.
- CompuGroup Medical has a dividend yield of 0.22%, offering a modest income stream for investors.
Competitors & Peers
Strengths
- Comprehensive product portfolio across multiple healthcare segments.
- Established presence in the European healthcare IT market.
- Strong gross margin of 83.6%.
- Focus on integrated healthcare solutions.
Weaknesses
- Relatively low profit margin of 1.5%.
- Dependence on regulatory compliance and healthcare policies.
- Limited presence in some emerging markets.
- High P/E ratio of 89.71.
Catalysts
- Ongoing: Increasing adoption of digital health solutions by healthcare providers and consumers.
- Ongoing: Expansion of integrated healthcare systems and data analytics capabilities.
- Upcoming: Potential strategic acquisitions to expand product offerings and market share.
- Ongoing: Government initiatives promoting electronic health records and telehealth services.
- Ongoing: Growing demand for IT security services in the healthcare sector.
Risks
- Potential: Intense competition from other healthcare IT providers.
- Potential: Evolving regulatory landscape and compliance requirements.
- Potential: Cybersecurity threats and data breaches.
- Potential: Economic downturns affecting healthcare spending.
- Ongoing: Currency risk associated with the ADR structure.
Growth Opportunities
- Expansion of Digital Health Solutions: CompuGroup Medical has the opportunity to expand its digital health solutions, including consumer portals and mobile apps. The digital health market is experiencing rapid growth, driven by increasing consumer demand for convenient and accessible healthcare services. By enhancing its digital offerings, CompuGroup Medical can attract new customers and increase revenue. The global digital health market is projected to reach $660 billion by 2025, presenting a substantial growth opportunity for the company.
- Integration of Healthcare Systems: The increasing demand for integrated healthcare systems presents a significant growth opportunity for CompuGroup Medical. Healthcare providers are seeking solutions that can seamlessly integrate data across different systems, improving efficiency and patient care. CompuGroup Medical can capitalize on this trend by developing and offering integrated solutions that connect ambulatory, pharmacy, hospital, and consumer health systems. This integration can lead to increased customer loyalty and higher revenue.
- Geographic Expansion: CompuGroup Medical can pursue geographic expansion to tap into new markets and increase its global presence. Emerging markets, in particular, offer significant growth potential due to increasing healthcare spending and the adoption of digital health technologies. By expanding into these markets, CompuGroup Medical can diversify its revenue streams and reduce its reliance on mature markets. This expansion requires careful market analysis and strategic partnerships to navigate local regulations and cultural differences.
- Strategic Acquisitions: CompuGroup Medical can pursue strategic acquisitions to expand its product portfolio and market share. Acquiring companies with complementary technologies or customer bases can accelerate growth and enhance the company's competitive position. Potential acquisition targets include companies specializing in telehealth, data analytics, or cybersecurity for healthcare providers. These acquisitions should be carefully evaluated to ensure they align with CompuGroup Medical's overall strategy and create synergies.
- Data Analytics and AI: CompuGroup Medical can leverage data analytics and artificial intelligence (AI) to improve its products and services. By analyzing healthcare data, the company can identify trends, predict patient outcomes, and personalize treatment plans. AI can also be used to automate tasks, improve efficiency, and reduce costs. Investing in data analytics and AI capabilities can enhance CompuGroup Medical's competitive advantage and drive innovation in the healthcare IT sector. The market for AI in healthcare is expected to reach $34 billion by 2025.
Opportunities
- Expansion into new geographic markets.
- Growth in the digital health solutions market.
- Strategic acquisitions to expand product offerings.
- Increased demand for integrated healthcare systems.
Threats
- Intense competition from other healthcare IT providers.
- Evolving regulatory landscape and compliance requirements.
- Cybersecurity threats and data breaches.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Established Customer Base: Long-standing relationships with a diverse customer base in the healthcare sector.
- Integrated Solutions: Comprehensive suite of integrated software solutions across ambulatory, pharmacy, hospital, and consumer health segments.
- Regulatory Expertise: Deep understanding of healthcare regulations and compliance requirements.
- Data Assets: Proprietary data assets and analytics capabilities that provide valuable insights to customers.
About CMPUY
CompuGroup Medical SE & Co. KGaA, founded in 1987 and headquartered in Koblenz, Germany, develops and sells software and IT solutions for the healthcare sector globally. The company operates through four key segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment offers practice management software and electronic medical records for physicians and medical centers, along with supplementary internet solutions. The PCS segment provides software applications for pharmacies, focusing on administrative and billing processes, and offers decision support for medication supply chain management. The HIS segment delivers clinical and administrative solutions for hospitals, rehabilitation centers, and medical laboratories. The CHS segment provides IT security services, data-based product offerings, software interfaces, and clinical decision-making support for healthcare providers, as well as digital healthcare platforms and mobile apps for consumers. CompuGroup Medical serves a diverse clientele, including pharmaceutical companies, health insurance companies, and individual consumers. Formerly known as CompuGroup Medical SE, the company rebranded in June 2020 to CompuGroup Medical SE & Co. KGaA, reflecting its continued evolution in the healthcare IT landscape.
What They Do
- Develops and sells software for ambulatory information systems (AIS).
- Provides software solutions for pharmacy information systems (PCS).
- Offers clinical and administrative solutions for hospital information systems (HIS).
- Creates consumer and health management information systems (CHS).
- Delivers IT security services for healthcare providers.
- Provides data-based product offers and software interfaces for information sharing.
- Offers clinical decision-making support and medication databases.
- Develops digital healthcare stock, consumer portals, and mobile apps.
Business Model
- Software Licensing: Generates revenue through licensing its software solutions to healthcare providers and pharmacies.
- Subscription Services: Offers subscription-based services for ongoing access to its software and related support.
- IT Services: Provides IT security services and data-based product offers to healthcare organizations.
- Data Analytics: Leverages healthcare data to provide insights and analytics to improve patient outcomes and efficiency.
Industry Context
CompuGroup Medical operates in the rapidly evolving healthcare IT sector. The industry is driven by increasing demand for digital health solutions, electronic health records, and integrated healthcare systems. The market is competitive, with key players including BITGF (Allscripts Healthcare Solutions), BTTAY (Cerner), CSWYF (Change Healthcare), DGWPF (Teladoc Health), and DWRKF (athenahealth). These companies compete on product offerings, technological innovation, and market reach. The healthcare IT market is expected to continue growing, fueled by government initiatives promoting electronic health records and the increasing adoption of telehealth services.
Key Customers
- Registered physicians and medical care centers.
- Pharmacies and pharmaceutical companies.
- Acute care hospitals and rehabilitation centers.
- Health insurance companies.
- Consumers seeking digital health solutions.
Financials
Chart & Info
CompuGroup Medical SE & Co. KGaA (CMPUY) stock price: Price data unavailable
Latest News
No recent news available for CMPUY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CMPUY.
Price Targets
Wall Street price target analysis for CMPUY.
MoonshotScore
What does this score mean?
The MoonshotScore rates CMPUY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Daniel Gotthardt
Unknown
Information on Daniel Gotthardt's background is not available in the provided data. Therefore, a detailed career history, education, and previous roles cannot be provided. His experience prior to managing 8299 employees at CompuGroup Medical SE & Co. KGaA is Unknown.
Track Record: Due to the limited information available, Daniel Gotthardt's key achievements, strategic decisions, and company milestones under his leadership cannot be detailed. His specific contributions to CompuGroup Medical SE & Co. KGaA's performance are Unknown.
CompuGroup Medical SE & Co. KGaA ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. CMPUY is an ADR representing shares of CompuGroup Medical SE & Co. KGaA, a German company. This allows U.S. investors to invest in the company without directly dealing with foreign exchanges.
- Home Market Ticker: Frankfurt Stock Exchange, Germany
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: CMPU
CMPUY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CompuGroup Medical SE & Co. KGaA has limited regulatory requirements and reporting standards compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies on this tier may not be required to file regular financial reports with the SEC, leading to less transparency for investors. Investing in OTC Other stocks carries higher risks due to the limited information available.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: OTC stocks often have limited financial disclosure, making it difficult to assess their true value and financial health.
- Low Liquidity: Trading volumes can be thin, leading to wider bid-ask spreads and difficulty in executing large trades.
- Price Volatility: OTC stocks can be more susceptible to price manipulation and volatility due to lower trading volumes.
- Regulatory Risks: OTC companies may not be subject to the same level of regulatory scrutiny as exchange-listed companies.
- Information Asymmetry: Limited access to information can create an uneven playing field for investors.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and announcements for any updates.
- Established Business Operations: CompuGroup Medical SE & Co. KGaA has been in operation since 1987, indicating a long-standing presence in the healthcare IT sector.
- Global Presence: The company operates worldwide, serving various healthcare providers and consumers.
- Diverse Product Portfolio: CompuGroup Medical offers a comprehensive suite of software and IT solutions across multiple healthcare segments.
- ADR Listing: The existence of an ADR, even at Level I, suggests some level of compliance and oversight.
CMPUY Healthcare Stock FAQ
What does CompuGroup Medical SE & Co. KGaA do?
CompuGroup Medical SE & Co. KGaA develops and distributes software and IT solutions for the healthcare industry. Its business is segmented into Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). These segments provide software and services to physicians, pharmacies, hospitals, and consumers, facilitating electronic medical records, administrative tasks, supply chain management, and digital health solutions. The company's offerings aim to improve efficiency, connectivity, and patient care across the healthcare ecosystem.
What do analysts say about CMPUY stock?
Analyst sentiment on CMPUY stock is currently unavailable due to limited coverage. Key valuation metrics include a P/E ratio of 89.71, a gross margin of 83.6%, and a dividend yield of 0.22%. Growth considerations center on the company's ability to capitalize on the increasing demand for digital health solutions and integrated healthcare systems. Investors should monitor the company's financial performance, competitive positioning, and regulatory compliance to assess its long-term growth potential.
What are the main risks for CMPUY?
The main risks for CMPUY include intense competition in the healthcare IT sector, evolving regulatory requirements, cybersecurity threats, and economic downturns affecting healthcare spending. The company's relatively low profit margin of 1.5% also poses a risk, as it limits its ability to invest in growth initiatives and withstand competitive pressures. Additionally, as an ADR, CMPUY is subject to currency risk, which can impact returns for U.S. investors. Investors should carefully consider these risks before investing in CMPUY.
What are the key factors to evaluate for CMPUY?
CompuGroup Medical SE & Co. KGaA (CMPUY) currently holds an AI score of 48/100, indicating low score. Key strength: Comprehensive product portfolio across multiple healthcare segments.. Primary risk to monitor: Potential: Intense competition from other healthcare IT providers.. This is not financial advice.
How frequently does CMPUY data refresh on this page?
CMPUY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CMPUY's recent stock price performance?
Recent price movement in CompuGroup Medical SE & Co. KGaA (CMPUY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive product portfolio across multiple healthcare segments.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CMPUY overvalued or undervalued right now?
Determining whether CompuGroup Medical SE & Co. KGaA (CMPUY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CMPUY?
Before investing in CompuGroup Medical SE & Co. KGaA (CMPUY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis pending for CMPUY, which may provide further insights.
- OTC market data may be limited and less reliable than exchange-listed data.